Alector: Holding Amid Pipeline Setback as ABC Brain Delivery Platform Awaits Clinical Validation

William Blair analyst Myles Minter has reiterated their neutral stance on ALEC stock, giving a Hold rating today.

Myles Minter has given his Hold rating due to a combination of factors tied to both pipeline uncertainty and future optionality. Following the failure and termination of latozinemab’s INFRONT-3 trial, Alector is pivoting to its ABC brain delivery platform, which has encouraging preclinical findings but still lacks human proof of concept, making risk–reward difficult to fully gauge at this stage.

The company’s cash runway into 2027 and plans to advance multiple ABC-based candidates, including AL137 and AL064, provide upside potential, particularly if they compare favorably with competing Alzheimer’s approaches. However, meaningful value inflection is likely contingent on clinical validation, especially from the Phase II PROGRESS-AD interim futility analysis of nivisnebart expected in the first half of 2026, so the analyst prefers to wait for these data before revisiting the rating.

In another report released today, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $2.50 price target.